Restasis Payors Defend Class Cert. Bid In Allergan Suit

Law360 (October 11, 2019, 6:26 PM EDT) -- A group of Restasis buyers on Friday defended class certification in their New York federal suit accusing Allergan of boosting profits by delaying a cheaper generic version of the dry-eye medication, saying they share numerous, common antitrust injuries.

Allergan filed papers the day before asking the court to turn down the certification bid, saying it's not justified because many brand-loyal customers wouldn't have dropped Restasis anyway, even with a generic on the market.

Generally, the multidistrict litigation claims Allergan used tactics such as fraudulently obtaining secondary patents and trying to get tribal immunity to stave off generic competition for the popular...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS